Article Text

Download PDFPDF
Short report
Keratinocytic epidermal nevi are associated with mosaic RAS mutations


Background Activating RAS mutations in the germline cause rare developmental disorders such as Costello syndrome. Somatic RAS mutations are found in approximately 30% of human cancers. Keratinocytic epidermal nevi (KEN) represent benign congenital skin lesions arranged along Blaschko's lines. A subgroup of KEN is caused by hotspot oncogenic FGFR3 and PIK3CA mutations in mosaicism, but the majority lack these mutations.

Methods This study screened 72 KEN for activating mutations in RAS genes and other oncogenes.

Results Activating RAS mutations were identified in 28/72 (39%) of KEN. HRAS was the most commonly affected oncogene (86%), with the HRAS p.G13R substitution representing a new hotspot mutation.

Conclusion These results indicate that activating RAS somatic mutations leading to mosaicism result in benign KEN of the skin. Given the prevalence of KEN, mosaic HRAS mutations appear to be more common in patients than germline ones. These findings identify KEN as a mosaic RASopathy and lend further support to the notion that genetic mosaicism is an important contributor to disease.

  • HRAS
  • KRAS
  • NRAS
  • mosaicism
  • epidermal nevus
  • dermatology
  • cancer: dermatological
  • academic medicine
  • cancer: urological
  • cell biology
  • genome-wide
  • other gastroenterology
  • pancreas and biliary tract

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.